Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
|Articles|November 17, 2011
- Psychiatric Times Vol 28 No 11
- Volume 28
- Issue 11
Medicaid Demonstration Aims to Reduce “Psychiatric Boarding”
Author(s)Stephen Barlas
A new Medicaid demonstration program slated to begin next year will pilot a solution to the problem of “psychiatric boarding,” which has plagued general hospitals for many years.
Advertisement
Array
Articles in this issue
almost 15 years ago
How We Age: A Doctor’s Journey Into the Heart of Growing Oldalmost 15 years ago
The Medication Check as Psychotherapeutic Opportunityalmost 15 years ago
Hippocrates Under Contractalmost 15 years ago
Dangerous New Treatment Guidelines for ADHD Unveiledalmost 15 years ago
Children and Pets: A Winning Combinationalmost 15 years ago
Witness to an Extreme Century: A Memoiralmost 15 years ago
Improving Suicide Risk Assessmentalmost 15 years ago
A Tribute to Max Fink, MDalmost 15 years ago
A New Report on Pain in America: Like Déjà Vu All Over Againalmost 15 years ago
The Tree of LifeAdvertisement
Related to this article
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Podcast: Not Always Panic. A Cardiologist and Psychiatrist on Reading a Racing Heart
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5